Aspen Neuroscience to Showcase Advances in Autologous Cell Therapy Development at 2024 Cell & Gene Meeting on the Mesa
SAN DIEGO and PHOENIX, Oct. 7, 2024 /PRNewswire/ — Presentations by Aspen Neuroscience Chief Scientific Officer Xiaokui Zhang, Ph.D. and Chief Technology Officer Kim Raineri will highlight the latest therapeutic and corporate developments, at the annual Cell & Gene Meeting on the Mesa, held this week in Phoenix, Ariz. and live-streamed globally. Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa
Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 30, 2024 /PRNewswire/ — Aspen Neuroscience Chief Financial Officer, Kameel Farag, will present this week at three biotechnology investor conferences, where he will provide company updates detailing Aspen’s latest developments and future strategic plans for treating neurodegenerative diseases, including Parkinson’s disease. About Aspen Neuroscience Aspen Neuroscience, Inc., headquartered in San Diego, is dedicated to autologous regenerative medicine. The company’s
Aspen Neuroscience Announces Dosing Completion of First Cohort in ASPIRO Phase 1/2a Trial for Parkinson’s Disease
SAN DIEGO and PHILADELPHIA , Sept. 26, 2024 /PRNewswire/ — Aspen Neuroscience announced today that it has successfully completed dosing of the first cohort of patients in the ASPIRO study. Surgical safety data from this cohort has been accepted for late breaking presentations this week at the MDS International Congress of Parkinson’s Disease and Movement Disorders, taking place in Philadelphia September 27
Dr. Andres Bratt-Leal to Present Preclinical Safety and Efficacy Data for ANPD001 at the 2023 World Parkinson Congress in Barcelona
SAN DIEGO, June 29, 2023 /PRNewswire/ — Next week at the upcoming World Parkinson Congress (WPC) 2023 in Barcelona, Spain, Aspen Neuroscience co-founder Andres Bratt-Leal, PhD, Senior Vice President, Research and Development, will present preclinical safety and efficacy data for the first time for ANPD001, Aspen’s iPSC-derived lead candidate for treatment of Parkinson’s Disease (PD). “Preclinical Safety and Efficacy of Dopamine
Dr. Andrés Bratt-Leal to Present at the 2023 International Society for Stem Cell Research Annual Meeting Focus Sessions
SAN DIEGO, June 14, 2023 /PRNewswire/ — Today Aspen Neuroscience, Inc. co-founder and Senior Vice President, Research & Development, Andrés Bratt-Leal, PhD, will present “Enabling Autologous iPSC-Derived Cell Therapies with Predictive Genomics,” during the Focus Sessions taking place during this week’s 2023 International Society for Stem Cell Research (ISSCR) Annual Meeting in Boston, Mass. His presentation will cover experiences
The new news in stem cell research
DEC 1, 2017 – PRESENTATION Empowerment Day 2017 – Parkinson’s Association of San Diego, San Diego, CA, USA
GENOMICS FOR STEM CELL-BASED THERAPIES
MAR 14-15, 2019 – PRESENTATIONFuture of Individualized Medicine – Scripps Research, La Jolla, CA, USA